4
Q.ꢀQ. YꢁAꢂ ET AL.
40:60 to 100:0) to afford subfractions C41–C42. Subfraction C42 was further purified through
Sephadex LH-20 (MeOH) column to afford compound 4 (12 mg). The CHCl (420 g) fraction
3
was loaded onto a silica gel CC and eluted with a gradient of petroleum ether/ethyl acetate
(
25:1, 15:1, 10:1, 5:1, 2:11:1 and 0:1) to give fractions B1–B10. Fraction B5 was subjected to
a silica gel column using a petroleum ether/acetone (50:1, 20:1, 10:1, 5:1, 2:11:1 and 0:1)
gradient system, finally obtaining six fractions B51–B56. Compound 2 (55 mg) was crystal-
lised from fraction B53. Fraction B9 was further purified through repeated silica gel and
Sephadex LH-20 (MeOH) columns to afford compound 3 (30 mg). Fraction B7 was subjected
to silica gel CC eluted with a gradient of petroleum ether/ethyl acetate (4:1, 3:1, 2:1 and 1:1)
to obtain fractions B71–B75. Compound 5 (8 mg) and 6 (8 mg) were yielded from B73 by
repeated silica gel and Sephadex LH-20 (MeOH) columns.
2
0
Cyperenoic acid-9-O-β-d-glucopyranoside (1): white powder; [ꢀ] −51.7 (c 0.10, MeOH);
D
−
1
+
IR (KBr): 3453, 1643 cm ; HR-ESI-MS: m/z 435.1988 [M + ꢂa] (Calcd for 435.1989, C H O ꢂa);
21
32
8
1
H ꢂMR (500 MHz, DMSO-d ): δ 1.49 (1H, dd, J = 13.2, 7.5 Hz, H-2a), 1.64 (1H, dt, J = 13.2,
6
9.8 Hz, H-2b), 2.51–2.61 (1H, overlapped, H-3a), 2.62–2.70 (1H, m, H-3b), 2.10–2.18 (1H, m,
H-6a), 2.51–2.61 (1H, overlapped, H-6b), 1.91 (1H, dt, J = 6.6, 3.2 Hz, H-7), 2.03 (1H, ddd,
J = 13.4, 7.1, 3.8 Hz, H-8a), 1.73 (1H, ddd, J = 13.4, 10.4, 2.6 Hz, H-8b), 3.04–3.13 (3H, over-
lapped, H-9, 3′, 5′), 1.97 (1H, dd, J = 10.1, 6.3 Hz, H-10), 0.76 (3H, s, H-12), 0.96 (3H, s, H-13),
0.99 (3H, d, J = 6.3 Hz, H-14), 4.10 (1H, d, J = 7.8 Hz, H-1′), 2.91 (1H, t, J = 8.3 Hz, H-2′), 3.00 (1H,
d, J = 9.1 Hz, H-4′), 3.64 (1H, dd, J = 11.6, 2.1 Hz, H-6′a), 3.39 (1H, dd, J = 11.6, 6.1 Hz, H-6′b).
13
C ꢂMR (126 MHz, DMSO-d ): δ 66.5 (C-1), 25.5 (C-2), 36.7 (C-3), 124.6 (C-4), 166.2 (C-5), 30.9
6
(C-6), 47.4 (C-7), 35.5 (C-8), 80.9 (C-9), 42.3 (C-10), 40.9 (C-11), 25.3 (C-12), 19.2 (C-13), 13.5
(C-14), 166.0 (C-15), 105.1 (C-1′), 73.9 (C-2′), 76.6 (C-3′), 70.2 (C-4′), 76.9 (C-5′), 61.3 (C-6′).
3
.4. Acid hydrolysis of 1
Compound 1 (2 mg) was hydrolysed with 5% HCl (3 mL) at 100 °C for 2 h. The mixture was
neutralised with 10% ꢂa CO and extracted with CH Cl (3 × 5 mL). The sugar was confirmed
2
3
2
2
to be d-glucose through comparison of the TLC (n-BuOH/EtOAc/pyridine/H O, 6:1:5:4) with
2
2
0
an authentic sample of glucose (R : 0.4) and by its optical activity ([ꢀ] +45.7, c 0.04, H O).
f
D
2
3
.5. Cytotoxic activity
−1
of each cell line (5 × 104 cells mL ) was seeded in 96-well microplates and incubated at
7 °C for 24 h. Then, the test compound (20 μM) was added and the microplates were further
3
incubated for 72 h. Compounds that inhibited 50% of the growth of the cancer cells were
evaluated again at six concentrations; each concentration of the compound was tested in
two parallel wells. Cisplatin was used as a positive control.
4
. Conclusions
One new patchoulane-type sesquiterpenoid glycoside, named cyperenoic acid-9-O-β-d-
glucopyranoside (1), together with five known sesquiterpenoids (2–6), was isolated from
the roots of C. crassifolius. All the isolated compounds showed no significant cytotoxic activity